Education
About Us
Working with TipRanks
Follow Us
Sagimet Biosciences, Inc. Class A (SGMT)
NASDAQ:SGMT
RESEARCH TOOLSreports
SGMT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.73 - $10.43
Previous CloseN/A
Volume1.06M
Average Volume (3M)2.46M
Market Cap
$241.41M
Enterprise Value$24.24M
Total Cash (Recent Filing)$151.25M
Total Debt (Recent Filing)$78.00K
Price to Earnings (P/E)―
Beta3.42
Next Earnings
Aug 25, 2025EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding30,674,854
10 Day Avg. Volume2,328,690
30 Day Avg. Volume2,458,664
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)0.67
Price to Sales (P/S)0.00
P/FCF Ratio-2.36
Enterprise Value/Market Cap0.10
Enterprise Value/Revenue6.06
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.20
Forecast
1Y Price Target
$39.67Price Target Upside404.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Sagimet Biosciences, Inc. Class A News
PremiumCompany Announcements
Sagimet Biosciences Elects New Directors at Annual Meeting
PremiumCompany Announcements
Sagimet Biosciences Announces Phase 3 Trial Success
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPositive topline results from a Phase 3 trial in China support denifanstat's strong efficacy and safety profile in treating moderate-to-severe acne.
Market PositionDenifanstat is seen as a potentially differentiated monotherapy or combination agent, making SGMT an attractive play on the broader NASH space.
Bears Say
Financing ConcernsThe company continues to explore financing options to support their Phase 3 monotherapy program for denifanstat in advanced fibrotic F2/F3 NASH, with management aiming to secure sufficient funding for the program prior to dosing patients.
Market CompetitionDenifanstat appears on par or slightly superior in terms of IGA response and inflammatory lesion reductions compared to Almirall's oral antibiotic Seysara.
Ownership Overview
10.54% Insiders
6.56% Mutual Funds
23.57% Other Institutional Investors
55.36% Public Companies and Individual Investors
SGMT FAQ
What was Sagimet Biosciences, Inc. Class A’s price range in the past 12 months?
Sagimet Biosciences, Inc. Class A lowest stock price was $1.73 and its highest was $10.43 in the past 12 months.
What is Sagimet Biosciences, Inc. Class A’s market cap?
Sagimet Biosciences, Inc. Class A’s market cap is $241.41M.
When is Sagimet Biosciences, Inc. Class A’s upcoming earnings report date?
Sagimet Biosciences, Inc. Class A’s upcoming earnings report date is Aug 25, 2025 which is in 56 days.
How were Sagimet Biosciences, Inc. Class A’s earnings last quarter?
Sagimet Biosciences, Inc. Class A released its earnings results on May 08, 2025. The company reported -$0.56 earnings per share for the quarter, beating the consensus estimate of -$0.666 by $0.106.
Is Sagimet Biosciences, Inc. Class A overvalued?
According to Wall Street analysts Sagimet Biosciences, Inc. Class A’s price is currently Undervalued.
Does Sagimet Biosciences, Inc. Class A pay dividends?
Sagimet Biosciences, Inc. Class A does not currently pay dividends.
What is Sagimet Biosciences, Inc. Class A’s EPS estimate?
Sagimet Biosciences, Inc. Class A’s EPS estimate is -0.51.
How many shares outstanding does Sagimet Biosciences, Inc. Class A have?
Sagimet Biosciences, Inc. Class A has 30,674,854 shares outstanding.
What happened to Sagimet Biosciences, Inc. Class A’s price movement after its last earnings report?
Sagimet Biosciences, Inc. Class A reported an EPS of -$0.56 in its last earnings report, beating expectations of -$0.666. Following the earnings report the stock price went down -4.192%.
Which hedge fund is a major shareholder of Sagimet Biosciences, Inc. Class A?
Currently, no hedge funds are holding shares in SGMT
Sagimet Biosciences, Inc. Class A Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.67 (404.07% Upside)
$39.67 (404.07% Upside)
Blogger Sentiment
Bullish
SGMT Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 20.4%
Last 30 Days ▲ 20.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
91.48%
12-Months-Change
Fundamentals
Return on Equity
-34.72%
Trailing 12-Months
Asset Growth
-24.86%
Trailing 12-Months
Company Description
Sagimet Biosciences, Inc. Class A
Sagimet Biosciences, Inc. Class A (SGMT) is a clinical-stage biopharmaceutical company specializing in the development of novel therapeutics targeting key metabolic pathways to treat diseases with unmet medical needs. The company focuses primarily on the development of innovative drugs for the treatment of liver diseases, cancer, and other metabolic disorders, leveraging its expertise in fatty acid synthase (FASN) inhibition.
SGMT Stock 12 Month Forecast
Average Price Target
$39.67
▲(404.07%Upside)